Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)
Author:
Affiliation:
1. Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India
2. Department of Pharmaceutical Sciences, Khalsa College of Pharmacy, Amritsar, India
Funder
Department of Science and Technology
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543776.2022.2130752
Reference79 articles.
1. Diego S, DassaultSystèmes BIOVIA, 2020. Discovery studio modeling environment, release 2020. DassaultSystèmes; b) Dias MVB, Tyrakis P, Domingues RR, Leme AFP, Blundell TL, et al. Mycobacterium tuberculosis Dihydrofolate Reductase Reveals Two Conformational States and a Possible Low Affinity Mechanism to Antifolate Drugs. Structure. 2014;22:94-103;c) Blakley RL, et al. Eukaryotic dihydrofolate reductase. AdvEnzymolRelat Areas Mol Biol. 1995;70:23–102.
2. Structural comparison of chromosomal and exogenous dihydrofolate reductase fromStaphylococcus aureusin complex with the potent inhibitor trimethoprim
3. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling
4. Chemical space ofEscherichia colidihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs
5. Effectiveness of Antimalarial Drugs
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unveiling the Connection: Viral Infections and Genes in dNTP Metabolism;Viruses;2024-09-03
2. Synthesis, In Silico, and In Vitro Evaluation of the Potential Antioxidant Activity of New Quinazoline Derivatives;Russian Journal of Bioorganic Chemistry;2024-08
3. Isolation of Arborescin from Artemisia absinthium L. and Study of Its Antioxidant and Antimicrobial Potential by Use of In Vitro and In Silico Approaches;Separations;2024-07-05
4. Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management;International Journal of Molecular Sciences;2024-03-02
5. Genome‐scale CRISPR–Cas9 screen identifies PAICS as a therapeutic target for EGFR wild‐type non‐small cell lung cancer;MedComm;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3